openPR Logo
Press release

Orphan Drugs Market Expected to Reach 214.14 Billion by 2022

05-12-2017 08:28 AM CET | Health & Medicine

Press release from: Scalar Market Research

Orphan Drugs Market Expected to Reach 214.14 Billion by 2022

According to the new market research report, "Orphan Drugs Market, by Indication Types (Oncology, Ophthalmology, Hematology, Cardiovascular, Neurology, and Others) - Global Revenue, Trends, Growth, Share, Size and Forecast to 2022", published by Scalar Market Research, the global orphan drugs market is expected to grow at a steady CAGR of 11.43% from 2016 to 2022. At the estimated growth rate, the orphan drugs market is expected to grow from USD 111.87 billion in 2016 and become worth USD 214.14 billion by 2022.

The global orphan drugs market report offers in-depth analysis of the market size (revenue), market share, major market segments, different geographic regions, key players, premium insights, technology trends and forecast to 2022. It also focuses on the key drivers and opportunities in this market.

Request Sample: https://www.scalarmarketresearch.com/request-sample.php?id=26

Buyers will receive 10% customization on this report.

Key findings of the report:

The growing government support to the manufacturers of the orphan drugs from both the developed and the developing countries is expected to be one of the key driving factors for the global orphan drugs market.

The increased tax concession and the dedicated programs to develop and revolutionize the orphan drugs production is also expected to be one of the major growth drivers for the orphan drugs market on the global scale.

The rapid rise in the instances of various diseases such as some rare forms of cancers along with the rapid technological advancements is also attributed to be the vital driving factors for the growth of the orphan drugs market during the forecast period.
Oncology expected to dominate the therapeutic area segment of the global market

Enquiry Before Buying: https://www.scalarmarketresearch.com/enquire-before-buy.php?id=26

According to the report, the oncology treatments are expected to hold the largest share in the global orphan drugs market during the forecast period. The metabolic disease segment, on the other hand, is expected to grow at the fastest rate during the next few years. The rising instances of rare forms of cancer and other diseases and the rising demand from around the world are expected to be some of the significant growth drivers for the market.

North America expected to become the largest market for orphan drugs

According to the report, the North America segment is expected to be the largest geographic segment of the global market, based on the overall market share, followed by Europe and Asia-Pacific. The Rest of the World segment, on the other hand, is expected to grow at the fastest CAGR during the forecast period. This growth is attributed to the changing government policies and the rising demand for the orphan drugs from these regions.

Browse Report Summary: https://www.scalarmarketresearch.com/market-reports/orphan-drugs-market

Key Benefits of the Report:

The report presents an in-depth analysis of the orphan drugs market while focusing on the existing and future trends to highlight the key growth areas and investment pockets of the market
The report provides valuable insights into the key technological and market trends expected to impact the orphan drugs market during the forecast period
The report provides clear understanding of the roles of the key players and stakeholders involved in the market growth during the forecast period

The orphan drugs market report provides analysis of the key players, including:

1.Amgen, Inc
2.Alexion Pharmaceuticals
3.Pfizer, Inc
4.Celgene Corporation
5.Novartis International AG.
6.Shire, plc
7.Hoffman-La-Roche
8.BioMarin Pharmaceuticals, Inc

About Scalar Market Research

Scalar Market Research, Inc. is a Chicago, U.S.-based market research and consulting firm that serves Fortune 1000 companies, leading businesses and upcoming organizations from around the world to help them achieve their business goal of sustainable revenue growth, utilizing Scalar's premium market research reports and consulting services to make critical strategic decisions.

Our real-time industry data tracking, with the help of advanced analytics and machine learning, offers our clients highly accurate 360-degreeperspective of key developments in niche markets. Our team of industry experts, with a thorough understanding of the global markets and cumulative industry experience spanning 100+ years, works relentlessly to help our clients realize their most important business goals.

Find out more about our services at: www.scalarmarketresearch.com

Contact:
8770 W Bryn Mawr Ave.
Suite 1300
Chicago, IL 60631
Tel.: +1-800-213-5170 (U.S./Canada Toll-free)
Email: sales@scalarmarketresearch.com
Follow us on LinkedIn: https://www.linkedin.com/company/scalar-market-research

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Orphan Drugs Market Expected to Reach 214.14 Billion by 2022 here

News-ID: 534006 • Views:

More Releases from Scalar Market Research

Cloud Field Service Management Market
Cloud Field Service Management Market
Cloud Field Service Management is a system developed for managing field operations through a mobile application or software. This software solution enables the companies to manage field resources such as vehicle location, field worker activity and ensure delivery of spare parts to the operational field. This solution assigns work according to the skills and geographical location of the field employee and checks inventory for the availability of spare parts. The
Oncology Information System Market Report Forecasts Impressive Growth by 2022 - Scalar Market Research
Oncology Information System Market Report Forecasts Impressive Growth by 2022 - …
Healthcare sector is extensively using digital tools to store patient data. Oncology information system tracks patient information such as diagnostic details and patient history. This also includes additional information such as treatment patterns and prescriptions. Overall, the key services provided by the system are patient information systems, treatment planning systems, consulting services, and implementation and maintenance systems. This report studies the current and future aspects of the oncology information system
DC Torque Tool Market Segmentation and Competitor Analysis Report - Scalar Market Research
DC Torque Tool Market Segmentation and Competitor Analysis Report - Scalar Marke …
DC torque tool could be a tool designed to use torque alternative device or to live torque. Historically manual torque tools were for the most part current in mechanical activities; but, within the past few years, adoption of DC torque tools has augmented considerably. DC torque tools will apply torque a lot of quicker than manual torque applying strategies and might additionally produce a high torque force as compared to
Public Safety LTE Market scrutinized in top research report for the forecast 2017-2022 - Scalar Market Research
Public Safety LTE Market scrutinized in top research report for the forecast 201 …
The government initiatives toward public safety, ability issues, and rising demand for remote-controlled operations and remote police work are propellant the expansion of the marketplace for infrastructure and services. The high range of users during this phase is that the major reason for a high share of this application within the aforementioned market. The Govt. initiatives on national safety and increasing expenditures on public safety and security square measure expected

All 5 Releases


More Releases for Orphan

Potential Opportunities of Orphan Drugs Market
As per Fortune Business Insights, the North America Orphan Drugs Market was worth US$ 67,136.0 Mn in 2017 and will continue to rise at a steady pace until 2025. This is mainly ascribable to the rising awareness among people regarding the use of novel drugs. In addition to this, North America is expected to offer attractive growth opportunities on the back of recent FDA approvals on the development of orphan
Orphan Drug Pipeline & Regulatory Insight 2025
Orphan Drug Pipeline & Regulatory Insight 2025" Report Highlights: Global Orphan Drug Market Overview: US$ 260 Billion Opportunity Global Orphan Drug market by Segment Regulatory Landscape: USA, Europe & Asia Orphan Drug Designation & Reimbursement Policy: USA, Europe & Asia Global Orphan Drug Clinical Pipeline Insight: 973 Drugs Marketed Orphan Drug Clinical Insight: 366 Drugs The global orphan drug market opportunity is expected to surpass US$ 260 Billion by 2025 as per
Orphan Drugs for Cancer Pipeline Analysis
A huge market opportunity is offered by small patient population which suffers from rare or orphan diseases. Among the category of new orphan drugs, Oncology account for the largest disease group in recent years. It has been observed that majority of the orphan drugs in the clinical stages are for rare cancer disease drugs, and are in the late stages of the pipeline. Some of the drugs are being developed
US Orphan Drug Pipeline Analysis
In recent years, the pharmaceutical industry has been experiencing a paradigm shift. While a large pool of patients was considered as a major source of revenue for pharma companies in the past, the focus is now gradually shifting to small sections of patients suffering from rare disease. In US, this pool of patients is gradually growing and orphan drugs are becoming an extremely attractive business proposition for the pharmaceuticals industry.
Europe Orphan Drugs Pipeline Analysis
“Europe Orphan Drugs Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various drug profiles under Orphan Drugs status in Europe. Research report covers all the ongoing drug development in various phases. Each drug profiles include detailed information like: Originator, Owner, Collaborator, Technology Provider, Licensee, Development Phase, Development Indications, Mechanism of Action, Chemical Formula, Country of Development and detailed analysis on the development process. The information for particular drug
Global Orphan Drug Pipeline Analysis
In recent years, the pharmaceutical industry has been experiencing a paradigm shift. While a large pool of patients was considered as a major source of revenue for pharma companies in the past, the focus is now gradually shifting to small sections of patients suffering from rare disease. In US & Europe, this pool of patients is gradually growing and orphan drugs are becoming an extremely attractive business proposition for the